Stuart Carroll is associate director, head of market access, UK & Ireland, at Biogen Idec. All views are his own Stuart is a senior health economist and market access expert specialising in pharmaceuticals and health policy. He studied a BA (Hons) in Politics and Economics (1st Class) at the University of Northumbria at Newcastle, an MSc in Health Economics (Distinction) from the University of York, and an MBA (Distinction) from Imperial Business School. Stuart currently heads up the market access, health economics and health policy functions for a biologics company having previously been responsible for the health economics and health outcomes functions in the UK for a leading pharmaceutical company specialising in vaccines. He is a member of the International Society for Pharmcoeconomics and Outcomes Research (ISPOR) and has authorship credits in a number of policy papers on topics including military healthcare, the National Institute for Health and Clinical Excellence (NICE), the Quality and Outcomes Framework (QOF), health education, value-based pricing (VBP), public health and obesity, and the role of pharmacy. In 2008, Stuart researched and wrote the Conservative Party’s official policy on NICE, ‘Improving Access to New Drugs: A Plan to Renew the National Institute for Health and Clinical Excellence’ and in late 2011 co-authored a policy paper looking at the future of hospice care with the Parliamentary Undersecretary of State for Health Services, Dr. Dan Poulter MP. Stuart is a former Chairman of the Bow Group Health & Education Policy Committee and former Editorial Adviser to Crossbow, the Bow Group’s magazine, having also served as Treasurer in 2010.
Vaccine evaluation process needs urgent reformSubscription
The Joint Committee on Vaccination and Immunisation needs to be more open about how it decides which vaccines should be recommended for use in the UK.